Effect of Riluzole on Alzheimer's Disease

Phase 3

• Conditions: Alzheimer's disease; Alzheimer Disease.

• Registration Number: IRCT20100126003181N4
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 March 2018

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Having of mild type of Alzheimer's Disease
Receiving one of the anticholinesterase drugs for treating Alzheimer's from three months ago
aged between 60-80

Exclusion Criteria

Having any other type of Dementia
Any history of using Memantine or Riluzole
History of using medications with glutamatergic interaction
History of alcohol and opium abuse
History of diseases such as Parkinson's disease, epilepsy, stroke, high blood pressure, uncontrolled diabetes, MS, mental retardation, CNS tumors, Huntington, subdural Hematoma, history of major psychiatric diseases
History of severe head trauma that results in loss of consciousness

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function assessment. Timepoint: The first day and the 90th day of study. Method of measurement: Using the test of Mini Mental State Examination (MMSE).;Assessment of memory. Timepoint: The first day and the 90th day of study. Method of measurement: Using the test of Delayed recall test.;Assessment of disease progression. Timepoint: The first day and the 90th day of study. Method of measurement: Using the Functional Assessment Staging Tool (FAST).

Secondary Outcome Measures

Name	Time	Method
Drug side effect. Timepoint: fourth week. Method of measurement: ask from patient.